19072-27-6

Upstream product

• 19072-28-7 5-methoxy-2-phenyl-1-propyl-indole 
• 5883-96-5 5-methoxy-2-phenylindole 
• 1006-94-6 5-methoxylindole 
• 98-80-6 phenylboronic acid 

Downstream Products

• 1415345-95-7 2-phenyl-1-propyl-1H-indol-5-yl trifluoromethanesulfonate 
• 1415345-96-8 N-(2-(tert-butyldimethylsilyloxy)ethyl)-2-phenyl-1-propyl-1H-indol-5-amine 
• 1415345-97-9 N-(2-(tert-butyldimethylsilyloxy)ethyl)-4,6-dichloro-N-(2-phenyl-1-propyl-1H-indol-5-yl)pyrimidine-5-carboxamide 
• 1415345-98-0 4,6-dichloro-N-(2-hydroxyethyl)-N-(2-phenyl-1-propyl-1H-indol-5-yl)pyrimidine-5-carboxamide 
• 1415345-99-1 4-chloro-6-(2-phenyl-1-propyl-1H-indol-5-yl)-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5(6H)-one 
• 1415345-11-7 4-amino-6-(2-phenyl-1-propyl-1H-indol-5-yl)-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-5(6H)-one 

Relevant academic research and scientific papers

NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS

This invention relates to novel compounds which are inhibitors of acyl coenzymeA: diacylglycerol acyltransferase 1 (DGAT-1), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of diseases related to DGAT-1 dysfunction or where modulation of DGAT-1 activity may have therapeutic benefit including but not limited to obesity, obesity related disorders, hypertriglyceridemia, hyperlipoproteinemia, chylomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, hepatitis C virus infection and acne or other skin disorders.